Loading ......
The protozoan parasite Trichomonas vaginalis, or T. vaginalis, is found in the urogenital tract and is distinguished by its flagella. It normally has a pear-shaped appearance, but under some physicochemical circumstances, it can also take on the shape of an amoeboid.
The diameter of each T. vaginalis organism is between 2 and 14 micrometers, and its length is between 10 and 20 micrometers. It has five flagella, four of which are at the front of the cell and are between seven and eighteen micrometers long. These flagella are in charge of motility and twisting motions. The fifth flagellum is embedded in the undulating membrane, about half the length of the cell, and supported by slender, non-contractile riblets. The T. vaginalis cell has a large nucleus with typical eukaryotic features, and its Golgi apparatus is highly developed. Due to the absence of mitochondria, T. vaginalis relies on hydrogenosomes for energy production.
T. vaginalis is an obligate parasite that primarily infects squamous epithelial cells in the reproductive tract and reproduces via binary fission. It thrives in anaerobic environments and obtains nutrients by phagocytosing bacteria, vaginal epithelial cells, and red blood cells, and can also be engulfed by macrophages. T. vaginalis has a big genome, with around 176,441,227 base pairs encoding around 60,000 proteins. T. vaginalis is typically spread by sexual contact between humans, and while its survival outside of the host is limited, it can live for more than three hours in moist conditions.
Figure1. Schematic drawing of T. vaginalis. (a) Anterior flagellum; (b) undulating membrane; (c) pelto; (d) costa; (e) hydrogenosomes; (f) axostyle.
(Source: Bouchemal K, et al. 2017)
Upon entering the host, T. vaginalis employs a series of molecular mechanisms to establish contact, adhere, and cause pathology.
First, T. vaginalis adheres to the host's epithelial cells through surface adhesion proteins. T. vaginalis undergoes significant morphological changes upon contact with epithelial cells, transforming from its typical pear shape to an amoeboid form. This transformation increases its contact area with the host cells, enhancing adhesion capabilities. Adhesion proteins such as AP23, AP33, AP51, AP65, and AP120 play crucial roles in this process. These proteins, known as adhesins, mediate the parasite's attachment to the host cell surface. Additionally, other surface proteins of T. vaginalis, such as fibronectin-binding proteins and lipophosphoglycan (LPG), also contribute to the adhesion process. LPG, a pure carbon lipid similar to the lipopolysaccharide structures of prokaryotes, is anchored on the parasite's surface via inositol-phosphoglycan, further enhancing T. vaginalis's adhesion capabilities.
Once adhesion is successful, T. vaginalis begins to invade the host epithelial cells, triggering a series of pathogenic signaling pathways. These pathways include mitogen-activated protein kinase (MAPK) pathways, such as c-Jun N-terminal kinase (pJNK), p38, and extracellular signal-regulated kinase 1/2 (ERK1/2) pathways, as well as the activation of nuclear factor kappa B (NF-κB) pathways. The activation of these pathways leads to the production of pro-inflammatory cytokines within the host cells, such as interleukin-8 (IL-8), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor-alpha (TNF-α), thereby initiating a local inflammatory response.
Figure 2. Morphological changes of T. vaginalis interacting with DU145 prostate cells: a) 5 mins, b) 30 mins, c) 60 mins, d) 90 mins. Panel (a) shows the normal cell control. After 5 mins, T. vaginalis disrupts the monolayer while retaining its pear shape.
(Source: Vazquez-Carrillo LI, et al. 2011)
During the pathogenic process, T. vaginalis exhibits significant immune evasion capabilities. T. vaginalis releases exosomes with a diameter of 30-150 nanometers into the host's bodily fluids. These exosomes contain various biological molecules from the parasite, such as proteins, lipids, RNA, and other small molecules, which can affect host cell proliferation and apoptosis, and alter host cell signaling pathways. By releasing exosomes, T. vaginalis can transfer its antigens or other immune-modulating factors to the host's immune system, interfering with the host's ability to recognize and eliminate the parasite, thus aiding in evading host immune surveillance.
Figure 3. A visual summary of the effects of T. vaginalis exosomes
(Source: Twu O, et al. 2013)
T. vaginalis's proteases can degrade host immunoglobulins (IgG, IgM, and IgA), thereby weakening the host's immune response. For example, the 60 kDa T. vaginalis protease (CP) not only degrades immunoglobulins but also provides nutrients to the parasite by breaking down hemoglobin. TvCP39 is another important protease that degrades IgA, IgG, and IgM molecules, further compromising the host's immune defense. Additionally, T. vaginalis can resist complement system attacks by degrading C3b, a mechanism particularly effective under iron-rich conditions. T. vaginalis can also evade host immune recognition through phenotypic variation and molecular mimicry. For instance, the surface antigens P270 and P230 are closely related to phenotypic variation, with P230's variation based on changes in antibody binding site accessibility, while P270's surface expression is regulated by dsRNA viruses, iron concentration, and phosphorylation states. P270 exhibits a typical eukaryotic transmembrane protein structure, playing a crucial role in the parasite's immune evasion. Furthermore, T. vaginalis can cloak itself with host plasma proteins to avoid being recognized as foreign by the host immune system.
T. vaginalis infection is one of the most common non-viral sexually transmitted diseases worldwide, causing a range of health issues in the urogenital system. In female patients, T. vaginalis primarily affects the vagina and cervix, often leading to vaginitis, cervicitis, and potentially chronic pelvic inflammatory disease (PID). Symptoms typically include increased vaginal discharge, unpleasant odor, itching, and discomfort in the vulva. Infection may also cause cervicitis, characterized by cervical congestion, erosion, and abnormal discharge. In severe cases, it can progress to endometritis or chronic pelvic inflammatory disease, which can damage reproductive health and increase the risk of ectopic pregnancy and infertility.
Although most infected males are asymptomatic, T. vaginalis infection can cause a variety of urogenital problems such as nongonococcal urethritis (NGU), prostatitis, and epididymitis. Symptoms may include burning while urinating, urethral discharge, urinary urgency and frequency, and discomfort in the lower abdomen or perineum.
During pregnancy, T. vaginalis infection can cause a series of serious complications, including preterm birth, low birth weight, and premature rupture of membranes (PROM). Studies have shown that the infection is closely related to PROM and neonatal low birth weight, which not only affects fetal development and health but also increases the risk of neonatal diseases and mortality.
The clinical presentation of T. vaginalis infection varies depending on sex, the severity of the infection, and the host's immune status. While many infected individuals may be asymptomatic, typical symptoms in females include a large amount of frothy, yellow-green, or gray vaginal discharge, often with an unpleasant odor. This discharge is typically due to damage to vaginal epithelial cells and inflammatory responses caused by the infection. Female patients often experience intense itching and burning in the vagina and vulva, particularly after urination or intercourse. Inflammation can also lead to redness, sensitivity, and tenderness in the vulva, affecting comfort during daily activities and sexual intercourse. Pain during intercourse (dyspareunia) is also common, as vaginal inflammation and dryness make sex painful, sometimes accompanied by slight bleeding after intercourse. Male patients generally have milder symptoms, with some experiencing a small amount of clear or whitish urethral discharge, burning sensation during urination, urgency, mild itching or discomfort in the urethra, and occasionally urinary frequency. Patients may experience dull pain or discomfort in the lower abdomen or perineum if the infection spreads to the prostate or epididymis.
In conclusion, Trichomonas vaginalis is an important protozoan parasite with intricate structural and functional adaptations that allow it to thrive and cause disease in the human urogenital tract. Its distinctive pear-shaped form, as well as enhanced adhesion and immune evasion mechanisms, demonstrate its propensity to cause persistent infections and a variety of reproductive health concerns. T. vaginalis infection can cause a wide range of symptoms, from minor discomfort to serious consequences like persistent pelvic inflammatory disease and poor pregnancy outcomes. Understanding the anatomy, pathogenic mechanisms, and related disorders of T. vaginalis is critical for establishing effective diagnostic, therapeutic, and preventive strategies.
Creative Diagnostics provides a variety of high-quality research tools for T. vaginalis, such as antigens, antibodies, and assay kits, to ensure the accuracy of your experiments. Please see the product page for more information and make your decision easily and swiftly.
References
| Target | Cat. No. | Product Name | Size | Species | Application | Detection Sample | |
| T. vaginalis | DTS054 | Trichomonas Vaginalis (T.V) Rapid Test Kit (Device/Cassette) | 20T | Quantitative | vagina secretion sample | Inquiry |
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| T. vaginalis | DMAB4429 | Anti-T. vaginalis Monoclonal antibody, Clone C986M | Mouse | IgG3 | LFIA | Inquiry |
| DMAB4430 | Anti-T. vaginalis Monoclonal antibody, Clone C987M | Mouse | IgG3 | IF, ELISA | Inquiry | |
| DMAB4431 | Anti-T. vaginalis Monoclonal antibody, Clone C988M | Mouse | IgG3 | IF, ELISA | Inquiry | |
| DMAB4432 | Anti-T. vaginalis Monoclonal antibody, Clone C990M | Mouse | IgG3 | IF, ELISA | Inquiry | |
| T. vaginalis p65 | DMAB4433 | Anti-T. vaginalis P65 Monoclonal antibody, Clone CDI676 | Mouse | IgG1 | IF, ELISA | Inquiry |
| T. vaginalis type 1 | DMABT-51617MT | Anti-T. vaginalis type 1 Monoclonal antibody, Clone 2407/267 | Mouse | IgG1 | IHC, ELISA, FC, WB | Inquiry |
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| T. vaginalis | DAG218 | Native T. vaginalis | N/A | KLH | ELISA | Inquiry |
| DAG-P2204 | T. vaginalis (full length) | N/A | KLH | N/A | Inquiry | |
| T. vaginalis p65 | DAGC591 | Recombinant T.Vaginalis P65 Antigen | E. coli | KLH | SDS-PAGE | Inquiry |
Loading ......